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Rationale
Patients previously prescribed one epinephrine auto-
injector device may be switched to an alternative device
by their pharmacist or physician - sometimes without
training on the new device. It is unclear whether “device
switches” without retraining compromise the ability to
deliver epinephrine.
Methods
We evaluated mothers of food-allergic children partici-
pating in a UK study of epinephrine auto-injectors (EAI),
1 year after they were first trained to use an EAI, either
Anapen or Epipen (old design). Participants’ ability to
deliver epinephrine using their device was assessed using
a simulated anaphylaxis scenario. Participants then
underwent repeat assessment using a different EAI
device, randomly allocated, without training on the new
device. The UK-approved EAIs Epipen (new/old designs),
JEXT or Anapen were used, or Intelliject, an EAI with
audio/visual prompts approved in North America as
AuviQ(tm) and AllerjectTM. ISRCTN29175528
Results
We evaluated ability to deliver epinephrine in 108 parti-
cipants. Overall success rates were similar using their
original EAI 68/108 (63%) to the new device 65/108
(60%; P=0.775). However the outcome differed signifi-
cantly for different types of device switch. Success rates
were lower when switching between Anapen and either
old Epipen, new Epipen or JEXT (6/18; 33%) compared
with switching from old Epipen to either new Epipen or
JEXT (30/42; 71%; P<0.009). Success rates were highest
when switching from Anapen or old Epipen to Intelliject
(26/28; 93%) compared with switching to other EAIs
(39/80; 49%; P=0.000).
Conclusions
The safety of EAI device switches varies according to
the specific device. Switches to Intelliject appear to be
safer than other forms of device switch.
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